

DAFTAR PUSTAKA

- Acs, B. *et al.* (2022) 'Systematically higher Ki67 scores on core biopsy samples compared to corresponding resection specimen in breast cancer: a multi-operator and multi-institutional study', *Modern Pathology*, 35(10), pp. 1362–1369. Available at: <https://doi.org/10.1038/s41379-022-01104-9>.
- Adiputra, P.A.T. and Sudarsa, I.W. (2021) 'Skoring Prognostik Survival Pasien Triple Negative Breast Cancer Berbasis Immunoscore', *JBN (Jurnal Bedah Nasional)*, 5(2), p. 65. Available at: <https://doi.org/10.24843/jbn.2021.v05.i02.p05>.
- Andrés-Sánchez, N., Fisher, D. and Krasinska, L. (2022) 'Physiological functions and roles in cancer of the proliferation marker Ki-67', *Journal of Cell Science*. Company of Biologists Ltd. Available at: <https://doi.org/10.1242/jcs.258932>.
- Arafah, M.A. *et al.* (2021) 'KI-67 LI Expression in Triple-Negative Breast Cancer Patients and Its Significance', *Breast Cancer: Basic and Clinical Research*, 15. Available at: <https://doi.org/10.1177/11782234211016977>.
- De Azambuja, E. *et al.* (2007) 'Ki-67 as prognostic marker in early breast cancer: A meta-analysis of published studies involving 12 155 patients', *British Journal of Cancer*, 96(10), pp. 1504–1513. Available at: <https://doi.org/10.1038/sj.bjc.6603756>.
- Badowska-Kozakiewicz, A.M. *et al.* (2019) 'Clinicopathological factors associated with novel prognostic markers for patients with triple negative breast cancer', *Archives of Medical Science*, 15(6), pp. 1433–1442. Available at: <https://doi.org/10.5114/aoms.2018.79568>.
- Bernandito, Ardean, *et al.* (2024). Hubungan Antara Ekspresi AEG-1 dan ki-67 Pada Triple Negative Breast Cancer Operable Dengan Disease Free Survival [Tesis tidak dipublikasikan]. Universitas Gadjah Mada.
- Bland, K.I., Chang, H.R. and Copeland, E.M. (2018) 'Modified radical mastectomy and simple mastectomy', in *The Breast: Comprehensive Management of Benign and Malignant Diseases*. Elsevier Inc., pp. 443-461.e3. Available at: <https://doi.org/10.1016/B978-0-323-35955-9.00031-3>.

- Chaudhary, L.N. (2020) 'Early stage triple negative breast cancer: Management and future directions', *Seminars in Oncology*. W.B. Saunders, pp. 201–208. Available at: <https://doi.org/10.1053/j.seminoncol.2020.05.006>.
- Cheang, M.C.U. *et al.* (2009) 'Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer', *Journal of the National Cancer Institute*, 101(10), pp. 736–750. Available at: <https://doi.org/10.1093/jnci/djp082>.
- Choi, S.B. *et al.* (2022) 'Ki-67 and breast cancer prognosis: does it matter if Ki-67 level is examined using preoperative biopsy or postoperative specimen?', *Breast Cancer Research and Treatment*, 192(2), pp. 343–352. Available at: <https://doi.org/10.1007/s10549-022-06519-1>.
- Cooper, R.G., Holland, J.F. and Glidewell, O. (1979) *ADJUVANT CHEMOTHERAPY OF BREAST CANCER*.
- Dalton, L.W. *et al.* (2000) *Histologic Grading of Breast Cancer: Linkage of Patient Outcome with Level of Pathologist Agreement*.
- Denkert, C. *et al.* (2013) 'Ki67 levels as predictive and prognostic parameters in pretherapeutic breast cancer core biopsies: A translational investigation in the neoadjuvant gepartrio trial', *Annals of Oncology*, 24(11), pp. 2786–2793. Available at: <https://doi.org/10.1093/annonc/mdt350>.
- Ferlay J *et al.* (2024) *Global Cancer Observatory: Cancer Today*. Lyon, France: International Agency for Research on Cancer.
- Gao, W. *et al.* (2019) 'Clinical validation of Ki67 by quantitative reverse transcription-polymerase chain reaction (RT-PCR) in HR+/HER2- early breast cancer', *Journal of Cancer*, 10(5), pp. 1110–1116. Available at: <https://doi.org/10.7150/jca.29337>.
- Geyer, F.C. *et al.* (2017) 'The Spectrum of Triple-Negative Breast Disease: High- and Low-Grade Lesions', *American Journal of Pathology*. Elsevier Inc., pp. 2139–2151. Available at: <https://doi.org/10.1016/j.ajpath.2017.03.016>.
- Giuliano, A.E., Edge, S.B. and Hortobagyi, G.N. (2018) 'Eighth Edition of the AJCC Cancer Staging Manual: Breast Cancer', *Annals of Surgical Oncology*. Springer New York LLC, pp. 1783–1785. Available at: <https://doi.org/10.1245/s10434-018-6486-6>.

- Goldhirsch, A. *et al.* (2013) ‘Personalizing the treatment of women with early breast cancer: Highlights of the st gallen international expert consensus on the primary therapy of early breast Cancer 2013’, *Annals of Oncology*, 24(9), pp. 2206–2223. Available at: <https://doi.org/10.1093/annonc/mdt303>.
- Hajizadeh, E. *et al.* (2018) ‘Prognostic cut point for breast cancer age of diagnosis’, *International Journal of Cancer Management*, 11(5). Available at: <https://doi.org/10.5812/ijcm.9291>.
- Halperin, E.C., Perez, C.A., and Brady, L.W. (2013) *Perez & Brady’s principles and practice of radiation oncology*. Seventh Edition. Lippincott Williams & Wilkins.
- Houvenaeghel, G. *et al.* (2021) ‘Lymphovascular invasion has a significant prognostic impact in patients with early breast cancer, results from a large, national, multicenter, retrospective cohort study’, *ESMO Open*, 6(6). Available at: <https://doi.org/10.1016/j.esmoop.2021.100316>.
- Hudis, C.A. and Gianni, L. (2011) ‘Triple-Negative Breast Cancer: An Unmet Medical Need’, *The Oncologist*, 16(S1), pp. 1–11. Available at: <https://doi.org/10.1634/theoncologist.2011-s1-01>.
- Keam, B. *et al.* (2011) ‘Ki-67 can be used for further classification of triple negative breast cancer into two subtypes with different response and prognosis’, *Breast Cancer Research*, 13(2). Available at: <https://doi.org/10.1186/bcr2834>.
- Khan, W. *et al.* (2017) *Anticancer screening of medicinal plant phytochemicals against Cyclin-Dependent Kinase-2 (CDK2): An in-silico approach*, *Advancements in Life Sciences* | www.als-journal.com. Available at: www.als-journal.com.
- Kock am Brink, M. *et al.* (2023) ‘Intratumoral heterogeneity affects tumor regression and Ki67 proliferation index in perioperatively treated gastric carcinoma’, *British Journal of Cancer*, 128(2), pp. 375–386. Available at: <https://doi.org/10.1038/s41416-022-02047-3>.
- Li, H. *et al.* (2015) ‘Ki67 as a predictor of poor prognosis in patients with triple-negative breast cancer’, *Oncology Letters*, 9(1), pp. 149–152. Available at: <https://doi.org/10.3892/ol.2014.2618>.

- Lin, N.U. *et al.* (2008) ‘Sites of distant recurrence and clinical outcomes in patients with metastatic triple-negative breast cancer: High incidence of central nervous system metastases’, *Cancer*, 113(10), pp. 2638–2645. Available at: <https://doi.org/10.1002/cncr.23930>.
- M. Duncan, S. and M. Seigel, G. (2016) ‘High-contrast enzymatic immunohistochemistry of pigmented tissues’, *Journal of Biological Methods*, 3(3), p. 1. Available at: <https://doi.org/10.14440/jbm.2016.122>.
- Morrison, L. and Okines, A. (2023) ‘Systemic Therapy for Metastatic Triple Negative Breast Cancer: Current Treatments and Future Directions’, *Cancers*. Multidisciplinary Digital Publishing Institute (MDPI). Available at: <https://doi.org/10.3390/cancers15153801>.
- Nascimento, R.G. do and Otoni, K.M. (2020) ‘Histological and molecular classification of breast cancer: what do we know?’, *Mastology*, 30. Available at: <https://doi.org/10.29289/25945394202020200024>.
- Perou, C.M. *et al.* (2000) *Molecular portraits of human breast tumours*. Available at: www.stanford.edu/molecularportraits/.
- Phillips, L., Gill, A.J. and Baxter, R.C. (2019) ‘Novel prognostic markers in triple-negative breast cancer discovered by MALDI-mass spectrometry imaging’, *Frontiers in Oncology*, 9(MAY). Available at: <https://doi.org/10.3389/fonc.2019.00379>.
- Prihantono, P., Hatta, M., Binekada, C., Sampepajung, D., Haryasena, H., Nelwan, B., Islam, A.A., *et al.* (2017) ‘Ki-67 expression by immunohistochemistry and quantitative real-time polymerase chain reaction as predictor of clinical response to neoadjuvant chemotherapy in locally advanced breast cancer’, *Journal of Oncology*, 2017. Available at: <https://doi.org/10.1155/2017/6209849>.
- Prihantono, P., Hatta, M., Binekada, C., Sampepajung, D., Haryasena, H., Nelwan, B., Asadul Islam, A., *et al.* (2017) ‘Ki-67 Expression by Immunohistochemistry and Quantitative Real-Time Polymerase Chain Reaction as Predictor of Clinical Response to Neoadjuvant Chemotherapy in

- Locally Advanced Breast Cancer’, *Journal of Oncology*, 2017, pp. 1–8.
Available at: <https://doi.org/10.1155/2017/6209849>.
- Prihantono, P. (2017) ‘Profile of mRNA Expression of Ki-67 in Breast Cancer Patients Pre- and Post- Chemotherapy’, *American Journal of Clinical and Experimental Medicine*, 5(1), p. 10. Available at: <https://doi.org/10.11648/j.ajcem.20170501.13>.
- Simm, H.P. *et al.* (2017a) ‘Comparison of immunohistochemistry with PCR for assessment of ER, PR, and Ki-67 and prediction of pathological complete response in breast cancer’, *BMC Cancer*, 17(1). Available at: <https://doi.org/10.1186/s12885-017-3111-1>.
- Simm, H.P. *et al.* (2017b) ‘Comparison of immunohistochemistry with PCR for assessment of ER, PR, and Ki-67 and prediction of pathological complete response in breast cancer’, *BMC Cancer*, 17(1). Available at: <https://doi.org/10.1186/s12885-017-3111-1>.
- Sobri, F.B. *et al.* (2017) ‘Manajemen terkini kanker payudara’, *Media Aesculapius* [Preprint].
- Sukumar, J. *et al.* (2021) ‘Triple-negative breast cancer: promising prognostic biomarkers currently in development’, *Expert Review of Anticancer Therapy*. Taylor and Francis Ltd., pp. 135–148. Available at: <https://doi.org/10.1080/14737140.2021.1840984>.
- Suyatno, R.K.A. *et al.* (2020) ‘Panduan penatalaksanaan kanker’, *PERABOI (Perhimpunan Ahli Bedah Onkologi Indonesia)* [Preprint].
- Swede, H. *et al.* (2016) ‘Mortality risk from comorbidities independent of triple-negative breast cancer status: NCI-SEER-based cohort analysis’, *Cancer Causes and Control*, 27(5), pp. 627–636. Available at: <https://doi.org/10.1007/s10552-016-0736-3>.
- Tréré, D. *et al.* (2009) ‘High prevalence of retinoblastoma protein loss in triple-negative breast cancers and its association with a good prognosis in patients treated with adjuvant chemotherapy’, *Annals of Oncology*, 20(11), pp. 1818–1823. Available at: <https://doi.org/10.1093/annonc/mdp209>.

- Turkman, Y.E. *et al.* (2015) 'Biologic, demographic, and social factors affecting triple negative breast cancer outcomes', *Clinical Journal of Oncology Nursing*, 19(1), pp. 62–67. Available at: <https://doi.org/10.1188/15.CJON.62-67>.
- Urruticoechea, A., Smith, I.E. and Dowsett, M. (2005) 'Proliferation marker Ki-67 in early breast cancer', *Journal of Clinical Oncology*, pp. 7212–7220. Available at: <https://doi.org/10.1200/JCO.2005.07.501>.
- Uxa, S. *et al.* (2021) 'Ki-67 gene expression', *Cell Death and Differentiation*, 28(12), pp. 3357–3370. Available at: <https://doi.org/10.1038/s41418-021-00823-x>.
- Valachis, A. *et al.* (2021) 'Treatment patterns, risk for hospitalization and mortality in older patients with triple negative breast cancer', *Journal of Geriatric Oncology*, 12(2), pp. 212–218. Available at: <https://doi.org/10.1016/j.jgo.2020.09.004>.
- Viale, G. *et al.* (2008) 'Predictive value of tumor Ki-67 expression in two randomized trials of adjuvant chemoendocrine therapy for node-negative breast cancer', *Journal of the National Cancer Institute*, 100(3), pp. 207–212. Available at: <https://doi.org/10.1093/jnci/djm289>.
- Webster, J.D., Solon, M. and Gibson-Corley, K.N. (2021) 'Validating Immunohistochemistry Assay Specificity in Investigative Studies: Considerations for a Weight of Evidence Approach', *Veterinary Pathology*. SAGE Publications Inc., pp. 829–840. Available at: <https://doi.org/10.1177/0300985820960132>.
- Widodo, I. *et al.* (2017) 'Prognostic value of clinicopathological factors for Indonesian breast carcinomas of different molecular subtypes', *Asian Pacific Journal of Cancer Prevention*, 18(5), pp. 1251–1256. Available at: <https://doi.org/10.22034/APJCP.2017.18.5.1251>.
- Wirtz, R.M. *et al.* (2016) 'Biological subtyping of early breast cancer: a study comparing RT-qPCR with immunohistochemistry', *Breast Cancer Research and Treatment*, 157(3), pp. 437–446. Available at: <https://doi.org/10.1007/s10549-016-3835-7>.

- Wu, Q. *et al.* (2019) 'Prognostic value of ki-67 in patients with resected triple-negative breast cancer: A meta-analysis', *Frontiers in Oncology*, 9(OCT). Available at: <https://doi.org/10.3389/fonc.2019.01068>.
- Ying, Z., Li, J. and Li, M. (2011) 'Astrocyte elevated gene 1: Biological functions and molecular mechanism in cancer and beyond', *Cell and Bioscience*. Available at: <https://doi.org/10.1186/2045-3701-1-36>.